Brief: Achiko Obtains CE Mark For AptameXTM Covid-19 Rapid Test
May 17 (Reuters) - ACHIKO AG ACHIN.S :
* OBTAINS CE MARK FOR APTAMEXTM COVID-19 RAPID TEST
* COMPANY EXPECTS TO HAVE APTAMEX IN WIDESPREAD COMMERCIAL
AVAILABILITY IN Q3 2022
* COMPANY EXPECTS TO HAVE APTAMEX IN WIDESPREAD COMMERCIAL
AVAILABILITY IN Q3 2022
* REGISTERED APTAMEX AND HAS OBTAINED A CE MARK, ALLOWING
PRODUCT
TO BE SOLD IN 27 COUNTRIES IN EU
Source text for Eikon: ID:nEQ8mcJGsa
Further company coverage: ACHIN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Achiko in Liquidation AG
See all newsBrief: Achiko AG Continues To Struggle To Connect Production To Sales In Indonesia
Swiss stocks - Factors to watch on December 21
Brief: Achiko AG Production And Sales Update
Brief: Achiko Commences Commercial Deliveries In Indonesia
Brief: Achiko AG Says It Expects To Commence Delivery To Sales And Marketing Contract With Nahdlatul Ulama On Commencement Of Mass Production